Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Integral Molecular Earns Back-to-Back Top Workplace Honors from The Philadelphia Inquirer
6/22/2026
USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular’s Paratope-PLUS™ CDR-Scanning
4/21/2026
Integral Molecular Appoints Cheryl Paes as Vice President of Commercial Strategy
3/23/2026
World Vaccine Congress
Oct 19-22, 2026
Amsterdam, Netherlands
2026 International Society for Vaccines Annual Congress
Oct 12th-14th, 2026
Antwerp, Belgium
SITC
Nov 4th-8th, 2026
Phoenix, Arizona
ACT
Nov 15th-18th
San Antonio, Texas
PEGS Europe
Nov 17th-19th
Lisbon, Portugal
Identification of the Seven Critical Residues that Control ZIKV-DENV Cross-reactivity to Engineer a Non-cross-reactive ZIKV Vaccine
Cell Reports, 2025
Redefining antibody patent protection using paratope mapping and CDR-scanning
Nature Biotechnology, 2025
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics
mAbs, 2024
Reporter Virus Particles and other tools to expedite vaccine and antibody development
Your research deserves a trusted ally. We are problem-solving enthusiasts ready with the right
tools to tackle your biggest scientific challenges.
Since 2001, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.
Integral Molecular’s technologies
continuously contribute to scientific discoveries featured in peer-reviewed publications, including in top journals.
Your success is our priority. We work hard to understand your needs, and we strive to exceed your expectations.
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.